<?xml version='1.0' encoding='utf-8'?>
<document id="25069798"><sentence text="Evaluation of the pharmacokinetic interaction between ticagrelor and venlafaxine, a cytochrome P-450 2D6 substrate, in healthy subjects."><entity charOffset="69-80" id="DDI-PubMed.25069798.s1.e0" text="venlafaxine" /></sentence><sentence text="Ticagrelor is a reversibly binding P2Y12 receptor antagonist used clinically for the prevention of atherothrombotic events in patients with acute coronary syndromes (ACS)"><entity charOffset="0-10" id="DDI-PubMed.25069798.s2.e0" text="Ticagrelor" /></sentence><sentence text=" Ticagrelor has been shown in vitro to be a weak inhibitor of cytochrome P-450 (CYP) 2D6, a clinically important enzyme for the metabolism of many drugs"><entity charOffset="1-11" id="DDI-PubMed.25069798.s3.e0" text="Ticagrelor" /></sentence><sentence text=" This study assessed the effects of coadministration of ticagrelor on the pharmacokinetics of the CYP2D6 substrate venlafaxine"><entity charOffset="56-66" id="DDI-PubMed.25069798.s4.e0" text="ticagrelor" /><entity charOffset="115-126" id="DDI-PubMed.25069798.s4.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.25069798.s4.e0" e2="DDI-PubMed.25069798.s4.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s4.e0" e2="DDI-PubMed.25069798.s4.e1" /></sentence><sentence text=" The impact of venlafaxine on ticagrelor pharmacokinetic parameters was also investigated"><entity charOffset="15-26" id="DDI-PubMed.25069798.s5.e0" text="venlafaxine" /><entity charOffset="30-40" id="DDI-PubMed.25069798.s5.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.25069798.s5.e0" e2="DDI-PubMed.25069798.s5.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s5.e0" e2="DDI-PubMed.25069798.s5.e1" /></sentence><sentence text="" /><sentence text="Healthy subjects (N = 22) received a single 180-mg oral dose of ticagrelor on days 1 and 9 and oral doses of venlafaxine on day 4 (37"><entity charOffset="18-19" id="DDI-PubMed.25069798.s7.e0" text="N" /><entity charOffset="64-74" id="DDI-PubMed.25069798.s7.e1" text="ticagrelor" /><entity charOffset="109-120" id="DDI-PubMed.25069798.s7.e2" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.25069798.s7.e0" e2="DDI-PubMed.25069798.s7.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s7.e0" e2="DDI-PubMed.25069798.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25069798.s7.e0" e2="DDI-PubMed.25069798.s7.e2" /><pair ddi="false" e1="DDI-PubMed.25069798.s7.e1" e2="DDI-PubMed.25069798.s7.e1" /><pair ddi="false" e1="DDI-PubMed.25069798.s7.e1" e2="DDI-PubMed.25069798.s7.e2" /></sentence><sentence text="5 mg BID) and days 5 through 10 (75 mg BID)" /><sentence text=" Plasma concentrations of ticagrelor, venlafaxine, and their metabolites (AR-C124910XX and O-desmethylvenlafaxine [ODV], respectively) were quantified for pharmacokinetic analyses"><entity charOffset="26-36" id="DDI-PubMed.25069798.s9.e0" text="ticagrelor" /><entity charOffset="38-49" id="DDI-PubMed.25069798.s9.e1" text="venlafaxine" /><entity charOffset="91-113" id="DDI-PubMed.25069798.s9.e2" text="O-desmethylvenlafaxine" /><pair ddi="false" e1="DDI-PubMed.25069798.s9.e0" e2="DDI-PubMed.25069798.s9.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s9.e0" e2="DDI-PubMed.25069798.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25069798.s9.e0" e2="DDI-PubMed.25069798.s9.e2" /><pair ddi="false" e1="DDI-PubMed.25069798.s9.e1" e2="DDI-PubMed.25069798.s9.e1" /><pair ddi="false" e1="DDI-PubMed.25069798.s9.e1" e2="DDI-PubMed.25069798.s9.e2" /></sentence><sentence text=" Safety and tolerability were assessed throughout the study" /><sentence text="" /><sentence text="Overall, 19 of 25 subjects were male; 14 were white, 10 were black, and 1 was Asian" /><sentence text=" Mean (SD) age was 26 (6) years, and mean (SD) body mass index was 24" /><sentence text="3 (2" /><sentence text="9) kg/m(2)" /><sentence text=" Ticagrelor had no effect on overall exposure to venlafaxine, as assessed by the AUC0-τ (geometric least squares mean ratio, 110"><entity charOffset="1-11" id="DDI-PubMed.25069798.s16.e0" text="Ticagrelor" /><entity charOffset="49-60" id="DDI-PubMed.25069798.s16.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.25069798.s16.e0" e2="DDI-PubMed.25069798.s16.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s16.e0" e2="DDI-PubMed.25069798.s16.e1" /></sentence><sentence text="32 ng · h/mL [90% CI, 106" /><sentence text="27-114" /><sentence text="52])" /><sentence text=" Venlafaxine Cmax was increased by 22% in the presence of ticagrelor (121"><entity charOffset="1-12" id="DDI-PubMed.25069798.s20.e0" text="Venlafaxine" /><entity charOffset="58-68" id="DDI-PubMed.25069798.s20.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.25069798.s20.e0" e2="DDI-PubMed.25069798.s20.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s20.e0" e2="DDI-PubMed.25069798.s20.e1" /></sentence><sentence text="83 ng/mL [90% CI, 111" /><sentence text="80-132" /><sentence text="75])" /><sentence text=" ODV AUC0-τ and Cmax were unaffected by coadministration with ticagrelor (98"><entity charOffset="62-72" id="DDI-PubMed.25069798.s24.e0" text="ticagrelor" /></sentence><sentence text="71 ng · h/mL [90% CI, 96" /><sentence text="61-100" /><sentence text="85] and 101" /><sentence text="44 ng/mL [90% CI, 98" /><sentence text="34-104" /><sentence text="65], respectively)" /><sentence text=" Venlafaxine had no effect on the Cmax or AUC0-∞ of ticagrelor (96"><entity charOffset="1-12" id="DDI-PubMed.25069798.s31.e0" text="Venlafaxine" /><entity charOffset="52-62" id="DDI-PubMed.25069798.s31.e1" text="ticagrelor" /><pair ddi="false" e1="DDI-PubMed.25069798.s31.e0" e2="DDI-PubMed.25069798.s31.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s31.e0" e2="DDI-PubMed.25069798.s31.e1" /></sentence><sentence text="54 ng/mL [90% CI, 85" /><sentence text="03-109" /><sentence text="61] and 89" /><sentence text="67 ng · h/mL [90% CI, 82" /><sentence text="78-97" /><sentence text="14]) or AR-C124910XX (106" /><sentence text="39 ng/mL [90% CI, 96" /><sentence text="10-117" /><sentence text="78] and 106" /><sentence text="32 ng · h/mL [90% CI, 97" /><sentence text="28-116" /><sentence text="21], respectively)" /><sentence text=" Ticagrelor and venlafaxine were well tolerated whether given alone or in combination"><entity charOffset="1-11" id="DDI-PubMed.25069798.s44.e0" text="Ticagrelor" /><entity charOffset="16-27" id="DDI-PubMed.25069798.s44.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.25069798.s44.e0" e2="DDI-PubMed.25069798.s44.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s44.e0" e2="DDI-PubMed.25069798.s44.e1" /></sentence><sentence text="" /><sentence text="Ticagrelor had no clinically relevant effect on the plasma levels of venlafaxine and its CYP2D6-generated active metabolite, ODV"><entity charOffset="0-10" id="DDI-PubMed.25069798.s46.e0" text="Ticagrelor" /><entity charOffset="69-80" id="DDI-PubMed.25069798.s46.e1" text="venlafaxine" /><pair ddi="false" e1="DDI-PubMed.25069798.s46.e0" e2="DDI-PubMed.25069798.s46.e0" /><pair ddi="false" e1="DDI-PubMed.25069798.s46.e0" e2="DDI-PubMed.25069798.s46.e1" /></sentence><sentence text=" On the basis of these data, ticagrelor is not expected to affect CYP2D6-mediated drug metabolism to a clinically relevant extent" /><sentence text=" Venlafaxine had no effect on the pharmacokinetics of ticagrelor"><entity charOffset="1-12" id="DDI-PubMed.25069798.s48.e0" text="Venlafaxine" /></sentence><sentence text="" /></document>